Dr. Sant P. Chawla

Dr. Sant P. Chawla
Medical Oncologist, Jaipur

MD, FRACP

  • 1 Hospital
  • Pioneering physician whose work in sarcoma oncology has brought him several accolades and recognition as one of the world’s foremost experts of sarcomas and sarcoma therapy
  • Holds medical licensures in both Texas and California
  • He is board certified in Internal Medicine and Medical Oncology
  • He is also the current Director of Medical Oncology at the UCLA-Santa Monica Hospital
  • Current Director of Medical Oncology at Orthopaedic Hospital
  • Current Director of Medical Oncology at Century City Hospital.
  • Also heads the Sarcoma Oncology Center in Santa Monica, CA where he leads clinical cancer research efforts and several ground-breaking cancer treatment approvals
  • Currently, he is involved in the study of Rexin-G, an innovative targeted therapy that utilizes retroviral agents to deliver cell-growth inhibiting components to specific areas of interest
  • He has been a teacher and mentor of hundreds of fellows, residents, and students at premiere institutions like the M.D. Anderson Cancer Center, where he was an assistant professor Department of Medicine-Melanoma/Sarcoma/Medical Gynecology/Oncology, and Cedars-Sinai Medical Center where he was a Co-Director of the Comprehensive Cancer Center
  • Currently, he serves on the clinical faculty at both the University of California, Los Angeles and the University of Southern California, as well as at the John Wayne Cancer Institute
  • In these positions, he finds great joy in guiding and teaching the next generation of physicians that will continue the advancement of a field that he helped build and continues to lead
  • American Board of Internal Medicine, 1985
  • American Board of Medical Oncology, 1987

Specialities

  • Medical Oncology

Expertise

Education

  • Medical degree and completed his residency training in Internal Medicine at the All India Institute of Medical Sciences in New Delhi
  • He went on to the Auckland Hospital in Auckland, New Zealand to begin his specialty training in medical oncology
  • Fellowship in medical oncology in New Zealand, at the Fellow Royal Australasian College of Physicians (F.R.A.C.P.)
  • He was invited to continue his fellowship in oncology at the prestigious M.D. Anderson Cancer Center of the University of Texas

Practice Information

Searoc Cancer Center, Jaipur

Searoc Cancer Center, Jaipur

S.K. Soni Hospital Premise, Sikar Road, Sector-5 Vidhyadhay Nagar, Jaipur, Rajasthan - 302013

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Sant P. Chawla and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Books and Chapter:Chawla S.P., Rosen G., Eilber F., Lowenbraun S., Eckardt J., Morton D. L., Selch M., Greenberg S. And Mirra J.: Cisplatin and Adriamycin as Neoadjuvant and Adjuvant Chemotherapy in the management of Soft Tissue Sarcoma.  Adjuvant therapy of Cancer VI, 1990.
  • Chawla S.P., Benjamin R. S., Jaffe N., Carrasco C. H., Raymond A. K., Ayala A. G., Wallace S., Armen T., Papadopoulos N. E. J., Plager C., Murray J. A.: Preoperative intra-arterial cisplatin and limb salvage surgery for patients with high grade osteosarcoma of the extremities.  IN: Adjuvant Therapy of Cancer V. (ed, Salmon S. E.), Grune & Stratton, Florida, 1987, pp 701-710.
  • Plager C., Bowen J. M., Fenoglio C. J., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. D. and Hersh E. M.: Adjuvant immunotherapy with Newcastle disease viral oncolysate.  IN: Adjuvant therapy of Cancer V (ed, Salmon S. E.), Grune & Stratton, Florida, 1987, pp 657-663.
  • Benjamin R. S., Chawla S.P., Hortobagyi G. N., ewer M. S., Mackay B., Legha S. S., Carrasco C. H., and Wallace S.: Continuous infusion chemotherapy and concomitant radiation therapy (eds, Rosenthal C. J. and Rotman M.), Plenum Press, New York, 1986, pp 19-25.
  • Ewer M. S., Chawla S.P., Carrasco C. H., Mackay B., Ali M. K., Haynie III T. P., and Benjamin R. S.: Correlation of ejection fraction and biopsy grades in patients receiving adriamycin.  IN: Proceedings of the 14th International Congress of Chemotherapy, Kyoto, 1985 (ed, Ishigami J.), University of Tokyo, 1985, pp 251-252.
  • Chawla S.P., Benjamin R. S., Abdul-Karim F. W., Ayala A. G., Papadopoulos N. E. J., Plager C., Romsdahl M., Jaffe N., Murray J. A.: Adjuvant chemotherapy of primary malignant fibrous histiocytoma of bone: Prolongation of disease-free and overall survival.  IN: Adjuvant Therapy of Cancer IV (eds, Jones S. E. and Salmon S. E.), Grune & Stratton, Florida, 1984, pp 621-629.
  • Benjamin R. S., Chawla S.P., Murray J. A., Carrasco C. H., Raymond A. K., Wallace S., Ayala A., Papadopoulos N. E. J., Plager C.: Preoperative chemotherapy for osteosarcoma: A treatment approach facilitating limb-salvage wit major prognostic implications.  IN: Adjuvant Therapy of Cancer IV (eds, Jones S. E. And Salmon S. E.), Grune & Stratton, Florida, 1984, pp 601-610.
  • Benjamin R. S., Chawla S.P., Carrasco C. H., Mackay b., Haynie T. P., Yap H. V., Blumenschein G. R., Holmes F., Ali M. K., and Bodey G. P.: Mitoxantrone cardiotoxicity: Evaluation by nuclear angiography and endomyocardial biopsy.  IN: Pharmanual (ed, Smyth J. F.) Sieber & McIntyre, Inc., New Jersey, 1984, pp 49-56.
  • Chawla S.P., Lazaro C.B., Hendifar A., Gupta R.R., Rana R., Nadadur R.  Chua V.S. A Phase II Study of VEGF-AS Veglin With Pemetrexed and Cisplatin, CAV Regimen, in the Treatment of Patients With Malignant Mesothelioma. 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, December 9-11, 2010. Abstract #161.
  • Butrynski J.E., Nadadur R., Jahan T., Chua V., Lazaro C.B., Chawla S. A Phase II Study of Nanoparticle Albumin-Bound (NAB) Paclitaxel in the Treatment of Patients with Unresectable or Metastatic Sarcoma. CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #901186.
  • Ganjoo K.N., Jahan T.M., Lazaro C.B., Chen A.L., Gupta R.R., Jain R.K., Chua V.S., Cranmer L.D., Chawla S.P. A Phase II Study of Low Dose TAG (Taxotere, Adriamycin, Gemcitabine) as Salvage Therapy for Soft Tissue Sarcoma. CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #896893
  • Chawla, S.P., et al. A Phase ½ Study of TH-302 in Combination with Doxorubicin in Soft Tissue Sarcoma. CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900676.
  • Chawla S.P., et al. Efficacy and Safety of Conatumumab Plus AMG 479 in Patients (PTS) with Advanced Sarcoma. CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #890126.
  • Demetri G.D., Le Cesne A., Yovine A., Maki R., Chawla S.P, et al. Yondelis ® (Trabectedin) hepatic safety profile as single-agent in soft tissue sarcoma (STS): Pooled analysis of phase II trials. CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #876470.
  • Pappo A., Patel S., Crowley J., Reinke D., Brownstein C., Chawla S., et al. A Phase II trial of R1507, a monoclonal antibody to the Insulin-Like Growth Factor-1 receptor (IGF1R) in patients with   recurrent or refractory bone and soft tissue sarcomas excluding ESFT.  CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900715.
  • Ganjoo K.N., Chawla S.P., et al. Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma. CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #890419.
  • Chawla S.P., et al. Denosumab in Giant Cell Tumor of Bone: Interim Results from a Phase 2 Study. CTOS 16th Annual Meeting, Nov. 11-13, 2010. Abstract #900789.
  • Roudier M., Blay J.Y., Chawla S., et al. Denosumab decreases proliferation in Giant Cell Tumor of Bone (GCTB). 10th International Conference on Cancer-Induced Bone Disease. Sept 22 – Sept 25, 2010.
  • Ganjoo K.N., Chawla S.P., et al. Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Infusions of Retrovector Encoding Mutant Anti-Cyclin G1 as Stand-alone Therapy for Chemotherapy-Resistant Bone and Soft Tissue Sarcoma. 2010 ASCO Abstract. June 4 - June 8, 2010. Abstract #: 10010.
  • Ignacio J.G., Chawla S.P., et al. A phase I/II study of intravenous rexin-g and reximmune-c for cancer immunotherapy: The GeneVieve protocol; 2010 ASCO Abstract. June 4 - June 8, 2010. Abstract #: 49252.
  • Chawla S.P., Staddon A.P., Messam C., Graham A.M., Mostafa Kamel Y.M. An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide; 2010 ASCO Abstract. June 4 - June 8, 2010.
  • Chawla S.P., Tabernero J., Kindler H.L., Chiorean E.G., LoRusso P., Hsu M., Haddad V., Bach B.A., Baselga J. Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors; 2010 ASCO Abstract. June 4 - June 8, 2010.
  • Langmuir V, Kroll S, Weiss G, Infante J, Borad M, Chiorean E G, Mita A, Ganjoo K, Chawla S, et al. TH-302, a novel tumor-selective hypoxia-activated prodrug (HAP): Phase 1 safety and activity as monotherapy and in combination with gemcitabine, docetaxel, pemetrexed and doxorubicin; 2010 New Zealand Society for Oncology Annual Conference Abstract.
  • Judson I, Blay J Y, Chawla S, Radford J, Le Cesne A, Verweij J, VonMehren M, Demetri G. Trabectidin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): results of a pooled analysis of five single-agent phase II studies; 2010 ASCO Abstract. June 4 - June 8, 2010
  • Chawla SP, et al. Targeting tumor hypoxia with TH-302: Phase I results with monotherapy and combination with chemotherapy.
  • Chawla S.P., Chua V.S., Fernandez L., Quon D., Saralou A., Blackwelder W.C., Hall F.L., Gordon E.M. Evaluation of the Safety and Efficacy of "Pathotropic" Nanoparticles Bearing a Dominant-Negative Cyclin G1 Construct (Rexin-G) as Monotherapy for Chemo-Resistant Osteosarcoma and Other Sarcomas -- Phase I/II and Phase II Studies; 2009 ASCO Annual Meeting. May 30, 2009. Abstract #10513. J Clin Oncol 27:15s, 2009.
  • Thomas D., Chawla S.P., et al. Denosumab for the Treatment of Giant Cell Tumor (GCT) of Bone: Final results from a Proof-of-Concept, Phase 2 Study. 2004015 study; 2009 ASCO Annual Meeting. May 30-June 1, 2009. Abstract #10510. J Clin Oncol 27:15s, 2009.
  • K.N. Ganjoo, L.D. Cranmer, S. Kroll, V.K. Langmuir, S.P. Chawla. Phase I/II Study of TH-302 Combined with Doxorubicin in Soft Tissue Sarcoma (STS): Preliminary Results; Submitted CTOS 2009
  • S.P. Chawla, L. Camacho, V.S. Chua, G. Abbadessa, B. Schwarz. A study of Palifosfamide in Combination with Doxorubicin: Safety and Preliminary Efficacy; CTOS 2008. IPM 1002 Study. November 13-15, 2008. Abstract # 35011.
  • V.S. Chua, S.P. Chawla, A. Kalra, D. Quon, K. Beltran, A Saralou, K.Y. Kita, E.M. Gordon, F.L. Hall. Phase I/II Study of Targeted Gene Delivery In Vivo – Intravenous Infusion of Pathotropic Nanoparticles bearing a Cytocidal Cyclin G1 Construct (Rexin-G) – Demonstrates Anti-Tumor Activity in Chemo-Resistant Metastatic Bone and Soft Tissue Sarcoma; CTOS 2008. C07-103, C07-110 Study. November 13-15, 2008. Abstract # 34963.
  • S.P. Chawla, V.S. Chua, A. Kalra, D. Quon, K. Beltran, A. Saralou, K.Y. Kita, F.L Hall, E.M. Gordon. Phase II Study of Pathotropic Nanoparticles Bearing a Cytocidal Cyclin G1 Construct (Rexin-G) Reveals Significant Anti-Tumor Activity with No Toxicity in Chemo-Resistant Metastatic Osteosarcoma; CTOS 2008. C07-110 Study. November 13-15, 2008. Abstract # 34960.
  • J.Y. Blay, S Chawla, et al. A Phase 1b Open-label Study of AMG 655 in Combination with Doxorubicin for the First-line Treatment of Patients with Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma; CTOS 2008. 20060324 study. November 13-15, 2008. Abstract # 34845.
  • S Chawla, et al. Initial Results of a Phase II Study of the Safety and Efficacy of the Apomab DR5 Agonist Antibody in Advanced Chondrosarcoma and Synovial Sarcoma Patients; CTOS 2008. APM 4171G Study. November 12-15, 2008. Abstract # 35010.
  • V. Mohan, T. Chawla, K. Alzwahereh, W. Jeong, K.Y.Kita, V.S. Chua, A. Kalra, G.S. Rana, S.P. Chawla. Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute; Proceedings of ASCO 2008, Volume 26, Abstract # 21506.
  • M. T. Schreeder, R.A. Figlin, J.J. Stephenson, L. Campos, S.P. Chawla, D.R. Spigel, A. Spira, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson. Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma; Proceedings of ASCO 2008, Volume 26, Abstract # 16024.
  • J.P. Allerton, B. Ebrahimi, M. T. Schreeder, P. Kaiser, S.P. Chawla, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson. Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC); Proceedings of ASCO 2008, Volume 26, Abstract # 14565.
  • S.P. Chawla, V.S. Chua, V. Mohan, K. Alzwahereh, A. Kalra, D. Quon, E.M. Gordon, F.L. Hall. Phase I/II study of targeted gene delivery in vivo – intravenous infusions of Rexin-G – demonstrate significant biologic activity by FDG PET-CT without toxicity in patients with progressive chemo-resistant sarcoma, breast cancer, and pancreatic cancer; Proceedings of ASCO 2008, Volume 26, Abstract # 14509.
  • D. Thomas, S.P. Chawla, K. Skubitz, A.P.Staddon, R. Henshaw, J.Y. Blay, J. Smith, Z. Ye, M. Roudier, S. Jun. Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study; Proceedings of ASCO 2008, Volume 26, Abstract # 10500.
  • Cesne A. L., Mehren M. V., Chawla S.P., et al. Assessing the Clinical Impact of Trabectedin in Patients with Leiomyosarcoma or Liposarcoma (L- sarcomas) Progressing Despite Prior Conventional Chemotherapy: Clinical Benefit Rate, Growth Modulation Index and Tumor Variation as Parameters of Treatment Effect in a Randomized International Trial of Two Trabectedin Dosing Regimens. ASCO-Journal of Clinical Oncology. Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10060.
  • Lagaru, R. Masamed, K.K. Sankhala, S.P. Chawla, L. Menendez, A. Fedenko and P.S. Conti, et al, Post-Ifosfamide therapy inflammation in musculoskeletal and soft-tissue sarcomas: Evaluation with F-18 FDG PET and PET/CT; Proceedings of 2006 SNM 53rd Annual Meeting, Pub. No. 1358, Ref. # 222045.
  • S.P. Chawla, E.W. Brien, R. Bhuva, L. Menendez, et, al. CHOP and Radiation: An Effective Therapy for Primary Lymphoma of the Bone. Proceedings of ASCO, 2003; Abstract # 2487.
  • D. Warr, R.J. Gralla, P.J. Hesketh, S.P. Chawla, et al, for the Aprepitant 052 and 054 Study Groups; Proceedings of ASCO 2003, Volume 22, Abstract # 2919.
  • S. Chawla, et al.   Newer Antiemetic and NK Inhibitor.   Proceedings of American Society of Clinical Oncology, Vol. 20, Abstract #1527, 2001.
  • C. Emmanouilides, B. Vescio, S. Chawla, J. Berenson, M. Territo, G. Schiller.  Successful Treatment of Multiple Myeloma Relapsed After High Does Chemotherapy With Non-Myeloablative Stem Cell Transplant.  UCLA Medical Center, Los Angeles, CA.  American Society of Clinical Oncology Official Abstract #144, 1999.
  • A. J. Bilchik, S. Chawla, D. M. Rose, S. Stern, K. P. Ramming.  Systemic Irinotecan (CPT-11) and Regional Chemotherapy Prolong Survival After Hepatic Cryosurgery in Patients With Metastatic Colon Cancer Refractory to 5- Fluorouracil (5-FU).  John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, CA and Century City Hospital, Los Angeles, CA.   American Society of Clinical Oncology Official Abstract #975, 1999.
  • S.P. Chawla, V. S. Chua, P. Bauer, T. Ganim, L. Menendez, E. Brien, J. Eckardt and F. Eilber.  Role of Alfa-Interferon in Reducing Risk of Metastasis in Patients With Poor Prognosis Osteosarcoma.  Orthopedic Hospital, Los Angeles, CA, UCLA School of Medicine, Los Angeles, CA, USC School of Medicine, Los Angles, CA and Century City Hospital, Los Angeles, CA.   1999 Annual Meeting of the American Society of Clinical Oncology, Abstract #151092.
  • L. R. Menendez, Matthew Tan, Milton Kiyabu and Sant P. Chawla.  Cryosurgical Ablation of Soft Tissue Sarcomas: A Phase 1 Study of Feasibility and Safety.  9th International Society of Limb Salvage, September 10-12, 1997, New York, New York.
  • P. Bostick, T. Sarantou, K. Huynh, A. Conrad, S.P. Chawla, A. Guiliano and D. Hoon.  A Multiple Marker RT-PCR Assay for Detection of Occult Metastasis in Frozen Sections of Sentinel Nodes from Breast Cancer Patients.  Joyce Eisenberg Keefer Breast Center, Santa Monica, CA and the National Genetics Institute, Los Angeles, CA.   Proceedings of American Society of Clinical Oncology, Vol. 16, 536, 1997.
  • A. E. Perez, S.P. Chawla, P. K. Kaywin, etc.: Efficacy and Safety of Oral Granisetron versus IV Ondansetron in Prevention of Moderately Emetogenic Chemotherapy-induced Nausea and Vomiting.  Mayo Clinic, Jacksonville, FL, UCLA School of Medicine, Santa Monica, CA, Oncology and Hematology Group of South Florida, Miami, FL; Smith Kline Beecham Pharmaceuticals, Collegeville, PA.  Proceedings of ASCO, Vol. 16, 149, 1997.
  • Benjamin R. S., Patel S. R., Armen T., Carrasco C. H., Raymond A. K., Ayala a. G., Chawla S.P., Yasko A. W. and Murray J.: The Value of Ifosfamide in Postoperative Neoadjuvant Chemotherapy of Osteosarcoma.  Proceedings of American Society of Clinical Oncology, vol 14, pp 516, #1690, 1995.
  • Barth A., Cabot M., Chawla S.P., Boasberg P., Foshag L., Gotis J. and Morton D. L.: Chemosensitivity for Malignant Melanoma Correlated With Clinical Response: Identification of a Subgroup of Patients Unlikely to Respond to Chemotherapy.  John Wayne Cancer Institute, Saint John’s Hospital and Health Center, Santa Monica, CA 90404.  Proceedings of American Society of Clinical Oncology, vol 13, pp 398, #1358, 1994.
  • Foshag L. J., Morton D. L., Nizze J. A. and Chawla S.P.: Response to Chemotherapy in Melanoma Patients After Active Specific Immunotherapy (ASI) with Melanoma Cell Vaccine   (MCV).John Wayne Cancer Institute, Saint John’s Hospital and Health Center, Santa  Monica, CA 90404.  Proceedings of American Society of Clinical Oncology, vol 12, pp 396, #1355, 1993.
  • Benjamin R. S., Patel S. R., Armen T., Carrasco C. H., Raymond A. K., Ayala A. G., Chawla S.P. and Murray J.: Primary Chemotherapy of Osteosarcoma of the Extremities - Long Term Follow-up.  Proceedings of American Society of Clinical Oncology, vol 12, pp 470, #1639, 1993.
  • Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.: High Dose Ifosfamide therapy in Metastatic Soft Tissue Sarcoma.  Proceedings American Association for Cancer Research, vol 30, 1990.
  • Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.: Role of Adriamycin and Cisplatin in therapy of Soft Tissue Sarcomas.  6th International Conference of Adjuvant therapy of Cancer, March 7-11.  Tucson, Arizona, 1990.
  • Chawla S.P., Rosen G., Lowenbraun S., Morton D. and Eilber F.: Role of High Dose Ifosfamide in Recurrent Osteosarcoma.  Proceedings of American Society of Clinical Oncology, #1210, vol 9, pp 310, 1990.
  • Rosen G., Chawla S.P., Hamburg S. and Lowenbraun S.: Phase II Study of High Dose Continuous Infusion of Dimethyl Traizeno Imidazole Carboxamide (DTIC) in Metastatic Leiomyosarcoma.  Proceedings American Society of Clinical Oncology, #1210, vol 9, pp 313, 1990.
  • Vadhan-Raj S., Fenoglio C., Chawla S.P., Broxmeyer H. E., Gutterman J. U. and Benjamin R. S.: Effects of Recombinant Human Granulocyte macrophage Colony Stimulating Factor (GM-CSF) on chemotherapy-induced Myelosuppression in Patients with Sarcoma.  Proceedings American Society of Clinical Oncology, #1254, vol 8, pp 322, 1989.
  • Benjamin R. S., Raymond A. K., Carrasco C. H., Chawla S.P., Armen T., Ayala A. G. and Murray J.: Primary Chemotherapy of Osteosarcoma of the Extremities with systemic Adriamycin and Intra Arterial Cisplatinum.  Proceedings American Society of Clinical Oncology, vol 8, #1251, pp 322, 1989.
  • Meistrich M. L., Chawla S.P. and DaCunha M. F.: Recovery of Sperm Production after chemotherapy with Adriamycin and Cisplatinum.  IV International Congress of Andrology, 1989.
  • Geopfert H., Spires J. R., Raymond A. K. and Chawla S.P.: Osteosarcoma of the Head and Neck.  32nd Annual Clinical Conference and 21st Annual Special Pathology Program.  Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi disciplinary Approach.  Sponsored by the University of Texas MD Anderson Cancer Center, November, 1988.
  • Chawla S.P., Benjamin R. S., Raymond A. K., Ayala A. G. and Murray J.: Cisplatin and Adriamycin as therapy for malignant fibrous histiocytoma of bone.  32nd Annual Clinical Conference and 21st Annual Special Pathology Program.  Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi disciplinary Approach.  Sponsored by the University of Texas MD Anderson Cancer Center, November, 1988.
  • Chawla S.P., Raymond A. K., Carrasco C. H., Ayala A. G., Murray J. and Benjamin R. S.: Telangiectatic Osteosarcoma: Response to Chemotherapy and Limb Salvage.  32nd Annual Clinical Conference and 21st Annual Special Pathology Program.  Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi disciplinary Approach.  Sponsored by the University of Texas MD Anderson Cancer Center, November, 1988.
  • Legha S., Ring S., Plager C., Papadopoulos N. E. J., Chawla S.P. and Benjamin R. S.: Evaluation of a Triple Drug Regimen containing Cisplatin (C), Vinblastine and DTIC in patients with Metastatic melanoma.  Proceedings of American Society of Clinical Oncology.  Vol. 7, pp 250, #968, 1988.
  • Chawla S.P., Gershenson D., Freedman R. S., Raber M., Gorski C., Kavanagh J., Smaldone L. and Wharton J. T.: A Randomized study of Carboplatin vs. Continuous Infusion of 5-Fluorouracil in Refractory Epithelial Ovarian Cancer.  Proceedings of American Society of Clinical Oncology.  Vol. 7, pp 148, # 572, 1988.
  • Paredes J., Chawla S.P., Raymond A. K., Carrasco C. H., Romsdahl N. M., Richli T. A. and Benjamin R. S.: Chemotherapy of the Osteosarcoma of the Pelvis.  Proceedings of American Association for Cancer Research #885, pp 223, vol. 29, 1988.
  • Chawla S.P., Kavanagh J. J., Freedman R. S., Raber M., Gershenson D., Edwards C. and Wharton T. J.: Pulmonary Toxicity and Limited Activity of Trimetrexate in Recurrent Carcinoma of Uterine Cervix.  Proceedings of American Association for Cancer Research #823, pp 207, vol 29, 1988.
  • Shin D. M., Gupta V., Chawla S.P., Donner L., Gutterman J. and Blick M.: Aberrant expression on N-MYC and C-K-RAS as well as overall expression of C-SIS in fresh uncultured human melanoma/sarcoma.  American Association of Cancer Research 28:20, 1987.
  • Papadopoulos N. E. J., Ring S., Plager C., Legha S., Chawla S.P. and Benjamin R. S.: Sequential use of vincristine (V), DTIC (D) and hydroxyurea (H) in advanced malignant melanoma.  American Society of Clinical Oncology 6:129, 1987.
  • Legha S., Fitz K., Papadopoulos N. E. J., Chawla S.P., Plager C. and Benjamin R. S.: Evaluation of intravenous (IV) N-acetylcysteine (NAC) as an un-protector against Ifosfamide (IFF) toxicity in patients with advanced sarcomas.  American Society of Clinical Oncology 6:129, 1987.
  • Carrasco C. H., Chawla S.P., Benjamin R. S., Raymond A. K., Ayala A. G., Murray J. and Wallace S.: Arteriographic prediction of tumor necrosis after primary treatment of osteosarcoma in adults.  American Society of Clinical Oncology 6:129, 1987.
  • Plager C., Papadopoulos N. E. J., Chawla S.P., Sandberg S., Legha S. and Benjamin R. S.: Ifosfamide (IFF) therapy for progressive pretreated metastatic sarcoma via compassionate IND.  American Society of Clinical Oncology 6:128, 1987.
  • Chawla S.P., Benjamin R. S., Jaffe N., Carrasco C. H., Raymond A. K., Ayala A., Wallace S., Armen T., Papadopoulos N. E. J., Plager C. and Murray J.: Preoperative Intra-arterial Cisplatin and Limb Salvage Surgery for Patients with High Grade Osteosarcoma of the Extremities.  5th International Conference of the Adjuvant Therapy of Cancer.  Tucson, Arizona, March, 1987.
  • Plager C., Bowen J. M., Fenoglio C. J., Papadopoulos N. E. J., Murray J., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. P. and Hersh E. M.: Adjuvant Immunotherapy of MD Anderson Stage III-B Malignant Melanoma.  5th International Conference of the Adjuvant therapy for Cancer.  Tucson, Arizona, March 11-14, 1987.
  • Carrasco C. H., Charnasangavej C., Richli W., Wallace S., Chawla S.P., Raymond A. K., Murray J. and Benjamin R. S.: Angiographic evaluation of response to preoperative chemotherapy in osteosarcoma.  72nd Scientific Assembly of the Radiological Society of north America, 1986.
  • Chawla S.P., Benjamin R. S., Raymond A. K., Carrasco C. H., Wallace S., Murray J. and Ayala A.: Role of chemotherapy in potential cure and limb salvage of high grade osteosarcoma of extremity.  Indian Society of Oncology, 2nd Biennial Conference.  Feb. 9-14, 1986, pp 165, 1986.
  • Legha S., Pickett S., Plager C., Papadopoulos N. E. J., Chawla S.P., Itri L. and Benjamin R. S.: Clinical efficacy of Roferon-A in metastatic melanoma: A comparison to two dose schedules.  American Society of Clinical Oncology 4:228, 1986.
  • Benjamin R.S., Chawla S.P., Carrasco C. H., Raymond A. K., Wallace S., Murray J., Ayala A. and Romsdahl M.: Primary chemotherapy of patients with osteosarcoma of an extremity.  American Society of Clinical Oncology 4:139, 1986.
  • Raymond A. K., Benjamin R. S., Carrasco C. H., Ayala A., Chawla S.P., Wallace S. and Murray J.: Osteosarcoma, preoperative chemotherapy: histological evaluation.  American Society of Clinical Oncology 4:138, 1986.
  • Kramer A., Fayssoux F., Atkinson E. N., Chawla S.P., Byers R., Goepfert H., Dimery I. and Hong W. K.: Malignant fibrous histiocytoma of the head and neck.  American Society of Clinical Oncology 4:138, 1986.
  • Plager C., Bowen J. M., Fenoglio C., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S., Savage H. E., Rosen R. D. and Hersh E. M.: Adjuvant Immunotherapy with Newcastle disease virus oncolysate of MD Anderson state III-B malignant melanoma.  American Society of Clinical Oncology 4:138, 1986.
  • Papadopoulos N. E. J., Armen T., Chawla S.P., Horwitz L., Spitzer G., Dicke K., Plager C. and Benjamin R. S.: High dose intravenous cytoxan, carmustine, etoposide and autologous bone marrow transplant for advanced refractory small round cell sarcomas in adults.  American Society of Clinical Oncology.  4:137, 1986
  • Chawla S.P., Benjamin R. S., Hortobagyi G. N., Ajani J. A. and Body G. P.: Decreased cardiotoxicity of 96-hour continuous infusion adriamycin compared with Epirubicin.  American Society of Clinical Oncology 4:44, 1986.
  • Chawla S.P., Benjamin R. S., Ayala A. G., Raymond A. J., Armen T., Carrasco C. H., Wallace S., Papadopoulos N. E. J., Plager C., Romsdahl M. M., Richli W. R. and Murray J.: Curative and limb-saving role of intra-arterial cis-platinum and systemic adriamycin in osteosarcoma.  American Association for cancer Research.  27:182, 1986.
  • Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H. and Mackay B: The cardiotoxicity of chemotherapeutic agents: evaluation by endomyocardial biopsy and nuclear Angiographic ejection fraction.  14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985.
  • Ewer M. S., Chawla S.P., Carrasco C. H., Mackay B., Ali M. K., Haynie III T. P. and Benjamin R. S.: Correlation of ejection fractions and biopsy grades in patients receiving adriamycin.  14th International Congress of Chemotherapy, Kyoto, Japan , June, 1985.
  • Chawla S.P., Benjamin R. S., Carrasco C. H., Raymond A. G., Papadopoulos N. E. J., Plager C. and Murray J. A.: Prognostically directed preoperative and postoperative chemotherapy and limb salvage surgery of high grade osteosarcoma.  14th International Congress of Chemotherapy, Kyoto, Japan, June, 1985.
  • Chawla S.P., Raymond A. K., Carrasco C. H., Papadopoulos N. E. J., Plager C., Romsdahl N. M., Ayala A. G., Wallace S., Murray J. A., Bodey G. P. and Benjamin R. S.: High rates of complete remission, limb salvage and prolonged survival in telangiectatic osteosarcoma after preoperative chemotherapy with intra-arterial cisplatinum and systemic adriamycin.  American Society of Clinical Oncology 4:152, 1985.
  • Papadopoulos N. E. J., Fayssoux R., Vellekoop L., Chawla S.P., Plager C., Spitzer G. and Benjamin R. S.: High Dose intravenous melphalan, carmustine, etoposide and bone marrow transplant for advanced refractory malignancy.  American Society of Clinical Oncology 4:151, 1985
  • Plager C., Bowen J. M., Fenoglio C., Papadopoulos N. E. J., Murray L., Chawla S.P., Benjamin R. S. and Hersh E. M.: Adjuvant immunotherapy with Newcastle disease virus oncolysate of MD Anderson state III-B malignant melanoma.  American Society of Clinical Oncology 4:151, 1985.
  • Ewer M. S., Ali M. K., Chawla S.P., Carrasco C. H., Lamki L., Mackay B., Balakrishnan P. V., Johnston D. A. and Benjamin R. S.: A comparison of resting and exercise ejection.  American Society of Clinical Oncology 4:150, 1985.
  • Papadopoulos N. E. J., Tenney D. M., Chawla S.P., Plager C. and Benjamin R. S.: Phase II study of bisantrene in advanced malignant melanoma.  American Association of Cancer Research.  26:174, 1985.
  • Benjamin R. S., Chawla S.P., Murray J. A., Carrasco C. H., Raymond A. K., Ayala A., Wallace S., Romsdahl M. M., Plager C. and Papadopoulos N. E. J.: Response to preoperative chemotherapy of osteosarcoma improves disease-free survival and the chances of limb salvage.  American Association for Cancer Research.  26:174, 1985.
  • Meistrich M. L., deCunha M. F., Chawla S.P., Plager C., Papadopoulos N. E. J. and Benjamin R. S.: Sperm production following chemotherapy for sarcomas.  American Association for Cancer Research.  26:170, 1985.
  • Benjamin R. S., Chawla S.P., Murray J. A., Wallace S., Carrasco C. H., Ayala A., Raymond A. K., Romsdahl M., Plager C. and Papadopoulos N. E. J.: Chemotherapy of primary osteosarcoma - A study of prognostic factors.  4th International Conference of the Adjuvant Therapy of Cancer.  Tucson, Arizona, March 21-24, 1984.
  • Chawla S.P., Benjamin R. S., Ayala A. G., Evans H., Papadopoulos N. E. J., Plager C., Jaffe N. and Murray J. A.: Adjuvant chemotherapy of primary malignant fibrous histiocytoma (MFH) of bone.  4th International Conference of Adjuvant Therapy of Cancer.  Tucson, Arizona, March 21-24, 1984.
  • Papadopoulos N. E. J., Tenney D. M., Benjamin R. S., Plager C., Chawla S.P. and Bodey G. P.: Phase II study of Bisantrene in advanced sarcoma.  American Society of Clinical Oncology 3:263, 1984.
  • Chawla S.P., Benjamin R. S., Legha S., Plager C., Papadopoulos N. E. J., Ewer M. S., Mackay B., Bodey G. P. and Wang A.: Detorubicin - an active anthracycline in metastatic melanoma.  American Society of Clinical Oncology 3:263, 1984.
  • Plager C., Papadopoulos N. E. J., Chawla S.P., Ayala A. G., Yap B. S., Romsdahl M. M., Martin R. G., Cangir A., Lindberg R. D., and Benjamin R. S.: A review of epithelioid sarcoma. American Society of Clinical Oncology 3: 262, 1984.
  • Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., Haynie III T. P., Yap H. Y., Blumenschein G. R., Holmes F., Ali M. K. and Bodey G. P.: Evaluation of Mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy.  American Society of Clinical Oncology 3:40, 1984.
  • Savaraj N., Lu K., Dimery I., Feun L., Burgess M. A. Guo Z., Chawla S.P. and Loo T. L.: Clinical pharmacology of homoharringtonine (HHT).  American Society of Clinical Oncology: 38, 1984.
  • Chawla S.P., McCredie K. B., Keating M. J., Estey E., Walters R. S., Bodey G. P., and Freireich E. J.: Phase II study of combination of 4-9 acridinylomino methanosulfon-M-anisidide (AMSA) and cis-platinum diamino-dichloride cisplatin (CDDP) in the treatment of adult acute leukemia (ALL).  American Society of Clinical Oncology 2:172, 1983.
  • Benjamin R. S., Chawla S.P., Ewer M. S., Wallace S. R., Mackay B., Carrasco C. H., Legha S. S., Mann G., Hortobagyi G. N., Valdivieso M., Ali M. K., and Haynie T. P.: Cardiac toxicity of high cumulative dose adriamycin by rapid or 24-96 hour continuous infusion.  American Society of Clinical Oncology 2:40, 1983.
  • Benjamin R. S., Chawla S.P., Plager P., Papadopoulos N. E., Yap B. S., Ayala A. G., Wallace S. R., Saunders P. P. And Murray J. A.: Primary malignant fibrous histiocytoma of bone - A chemotherapy responsive tumor.  American Association for Cancer Research 24:144, 1983.
  • Chawla S.P., Mann G. Benjamin R. S., Legha S. S., Mackay B., Ewer M. S., Ali M. K., Carrasco C. H., Hortobagyi G. N., Wallace S. R., Valdivieso M., Kim E. E., and Haynie T. P.: Monitoring of adriamycin cardiotoxicity beyond the conventional limits of 500 mg/m2.  American Association of Cancer Research 24:134, 1983
  • Some of his main areas of research include 
  • Preoperative chemotherapy of Osteosarcoma
  • Ewing’s sarcoma, and soft tissue sarcoma
  • Intra-arterial chemotherapy in sarcoma and gynecologic malignancies; study of oncogenes in sarcoma, melanoma, and gynecologic malignancies
  • The role of monoclonal antibodies in diagnosis and treatment of metastatic melanoma
  • The role of GM-CSF in amelioration of chemotherapy induced myelosuppression; and limb salvage surgery in Osteosarcoma, Ewing’s Sarcoma, and gynecologic malignancies
  • Dr. Chawla has been extensively involved with sarcoma drugs of the past and present, and his expertise will likely serve as a foundation for the development of future treatments as well
  • To date, he has published or contributed to over 100 research publications dealing with the nature and the treatment of sarcomas
  • His publications have illuminated several little known aspects of the disease and have gone on to support breakthrough studies and treatments in sarcoma oncology
  • Ganjoo K., Cranmer L.D., Butrynski J., Rushing D., Adkins D., Okuno S.H., Lorente G., Kroll S., Langmuir V., and Chawla S. A Phase I study of the Safety and Pharmacokinetics of the Hypoxia-activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma. Submitted to Journal of Clinical Oncology: Sept. 2010
  • Hall, F.L., Levy J.P., Reed R.A, Petchpud, W.N., Chua V.S., Chawla S.P., Gordon E.M. Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery. Oncology Reports (2010) 24, 829-833
  • Chawla S.P., Chua V.S., Fernandez L., Quon D., Blackwelder W.C., Gordon E.M., Hall F.L. Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer. Molecular Therapy (2010) 18 2, 435–441. doi:10.1038/mt.2009.228
  • Demetri G.D., Chawla S.)., et al. Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules. Journal of Clinical Oncology, Vol 27, No 25 (September 1), 2009: pp. 4188-4196
  • Sankhala K.K., Chawla S.P. Clinical Case Review: Desmoplastic Small Round Cell Tumor: Current Treatment Approach and Role of Targeted Therapy. Clin Adv Hematol Oncol. 2009 Jul;7(7):476-8.
  • Sonis S., Treister N.,Chawla S.P., Demetri G., Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin (mTOR) in cancer patients. Cancer. Submitted February 25, 2009            
  • Birch R., Chawla S.P., Sarcoma Oncology Center. Perifosine as an active agent in the treatment of patients with advanced sarcoma. ASCO-Journal of Clinical Oncology. Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10059
  • Morgan J. A., Le Cesne A., Chawla S.P., Mehren M. Von, Schuetze S., Casali P.G., Nieto A., Elsayed Y., Izquierdo M. A. and Demetri G. Yondelis Sarcoma Study Group. Randomized Phase II study of Trabectedin in patients with Liposarcoma and Leiomyosarcoma after failure of prior anthracylines (A) and Ifosfamide (I). ASCO-Journal of Clinical Oncology. Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10060
  • Chawla S.P., Tolcher A. W., Staddon A. P., Schuetze S., D’Amato G. Z., Blay J. Y., Loewy  J., Kan R. and Demetri G. D., Century City Doctor’s Hospital. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: Update of phase II trial. ASCO-Journal of Clinical Oncology. Vol 25, No. 18S (June 20, 2007 Supplement), 2007: 10076
  • Thomas D., Chawla S.P., Skubitz K., Smith J., Ye Z., Jun S. Effects of  Denosumab in the treatment of Giant Cell Tumor of Bone: Preliminary results from an open-label phase 2 study. CTOS 2007. 2004015 study. Aspire ID 1-V7VJ. June 18, 2007
  • Chawla S.P., A.W. Tolcher, A.P. Staddon, S.M. Schuetze, G.Z. D’Amato, J.Y. Blay, K.K. Sankhala, S.T. Daly, V.M. Rivera, G.D. Demetri. AP23573 Sarcoma Phase II Trials, a novel mTOR inhibito, in patients (pts) with advanced soft tissue or bone sarcomas. Journal of Clinical Oncology, Vol 24, No. 18S (June 20 Supplement), 2006: 9505
  • Chawla S.P., Sankhala K. K., Century City Doctors Hospital. AP23573: A Review of Recent Results, AP23573 is a targeted cancer therapy that inhibits the activity of mTOR, a cellular enzyme that plays a key role in cell growth and proliferation. The Liddy Shriver Sarcoma Initiative, Newsletter Vo3No4, http://www.liddyshriversarcomainitiative.org/Newsletters/V02 N04/AP23573/ap23573.htm, copyright 2005
  • S.P. CHAWLA, S.M. Grunberg, R.J. Gralla et al.  Establishing the Dose of MK-0869, an Oral NK1 Antagonist, for the   Prevention of Chemotherapy-Induced Nausea and Emesis, Cancer 2003; 97:2290-300
  • P.J. Hesketh, S.M. Grunberg, R.J. Gralla, D.G. Warr, F. Roila, R.D. Wit, S.P. Chawla, et.al. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High Dose Cisplatin- The Aprepitant Protocol 052 Study Group. Journal of Clinical Oncology, Vol.21, No 22, #4112- 4119, (November 15) 2003
  • Benjamin R. S., Chawla S.P., Carrasco C.H., Raymond A. K., Murray J. A., and Armen T. O.  Primary chemotherapy for Osteosarcoma with systemic adriamycin and intra-arterial cisplatin.  Cancer Bulletin, vol 42:5, 314-317, 1990.
  • Geopfert H., Raymond A. K., Spires J. R., Chawla S.P., Wolf P. F., Lee Y., and Batsakis J. G.  Osteosarcoma of the Head and Neck.  Cancer Bulletin, vol 42:5, 347-354, 1990
  • Carrasco C. H., Claringsangarej C. O., Raymond A. K., Richli W. R., Wallace S., Chawla S.P., Ayala A. G.  Osteosarcoma: Angiographic Assessment of Response to Preoperative Chemotherapy.  Radiology 170:839-342, 1989.
  • Meistrick M. L., Chawla S.P., Da Cunha M. F., Johnson S. L., Plager C., Papadopalous N. E., Lipsultz L. I., Benjamin R. S.  Recovery of Sperm Production After Chemotherapy for Osteosarcoma Cancer.  63:2115-2123, 1989.
  • Evans H. L., Chawla S.P., Simpson C., Finn K. P.  Smooth Muscle Neoplasms of the Uterus other than Ordinary Leiomysarcoma.  A Study of 46 cases with Emphasis on Diagnostic Criteria and Prognostic Factors.  Cancer 62:2239-2247, 1988
  • Chawla S.P., Yap B. S., Tenny D. M., Bodey G. P. and Benjamin R. S.: Phase I Study of Weekly-Administered Iproplatin [Cisdichloro-transdihydroxy-bis-isoprophylamine platin (chip, JM9)].  Investigational New Drugs G:311-317, 1988
  • Shin D. M., Gupta V., Ludvik D. , Chawla S.P., Benjamin S., Gutterman J. and Blick M.  Aberrant Oncogene Expression in Uncultured Human Sarcoma and Melanoma.  Anticancer Research 7:1117-1124, 1987
  • Raymond A. K., Chawla S.P., Carrasco C. H., Ayala A. G., Fanning C. V., Grive B., Armen T., Plager C., Papadopoulos N. E. J., Edeiken J., Wallace S., Jaffe N., Murray J. A., and Benjamin R. S.: Osteosarcoma Chemotherapy Effect: A Prognostic Factor.  Sem Diag Path 4:212-236, 1987
  • Legha S. S., Papadopoulos N. E. J., Plager C., Ring S., Chawla S.P., Evans L. M., Benjamin R. S.: Clinical Evaluation of Recombinant Interferon alfa-2A (Roferon-A) in Metastatic Melanoma using Two Different Schedules.  J. Clin Oncol 5:1240-1246, 1987
  • Chawla S.P., (Australian and New Zealand Breast Cancer Trial Group).  A Randomized trial in Postmenopausal patients with Advanced Breast Cancer Comparing endocrine and Cytotoxic Therapy Given Sequentially or in Combination.  J. Clin Oncol. 4:186-193, 1986
  • Johnson S., Tetu B., Ayala A. G., and Chawla S.P.: Chondro-sarcoma with Additional Mesenchymal component (“de-differentiated Chondrosarcoma) Part I: A Clinicopathological study of 26 cases.  Cancer 58:278-286, 1986
  • Schwartz M., Chawla S.P., Harvey V., Kay R., Mak D., Manson B., Probert J., Stephens E., Wood H., et al: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination.  By the Australian and New Zealand Breast Cancer Trial Group, Clinical Oncology Society of Australia.  J. Clin Oncol. 4:186-193, 1986
  • Dajani J. A., Dimery I., Chawla S.P., Pinnamaneni K., Benjamin R. S., Legha S. S., and Krakoff I. H.: Phase II Studies of homoharringtone in patients with advanced malignant melanoma; sarcoma; head and neck, breast and colorectal carcinomas.  Cancer Treatment Reports 70:375-379, 1986
  • Murray J. A., Jesspu K., Romsdahl M., Raymond K., Ayala A., Carrasco H., Wallace S., Jaffe N., Benjamin R., Plager C., Papadopoulos N., and Chawla S.P.: Limb-salvage surgery in osteosarcoma: Early experience at MD Anderson Hospital and Tumor Institute.  Cancer Treatment Symposia 3:131-137, 1985
  • Benjamin R. S., Holmes F., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., Dukart G., and Bodey G. P.: Evaluation of Novantrone Cardiac Toxicity by Nuclear Angiography and endomyocardial biopsy: An update.  Proceedings of the Current Status of Novantrone.  Pp 69-73, 1985
  • Chawla S.P., Legha S. S., and Benjamin R. S.: Detorubicin - An active anthracycline in untreated metastatic melanoma.  J. Clin Oncol 3:1529-1534, 1985
  • Abdul-Karim F. W., Ayala A. G., Chawla S.P., Jing B. S., Geopfert H.: Malignant Fibrous Histiocytoma of Jaws: A Clinicopathologic study of eleven cases.  Cancer 56:1590-1596, 1985
  • Benjamin R. S., Chawla S.P., Ewer M. S., Carrasco C. H., Mackay B., and Holmes F.: Evaluation of Mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update.  Invest New Drug 3:117-121, 1985
  • Chawla S.P., Buzdar A., Hortobagyi G., and Blumenschein G.: Tumor-associated fever in breast cancer.  Cancer 53:1596-1599, 1984
  • Benjamin R. S., Murray J. A., Wallace S., Ayala A., Chawla S.P., Raymond A. K., Carrasco C. H., Romsdahl M. M., Papadopoulos N. E. J., and Plager C: A judicious approach to limb salvage.  Cancer Bulletin 36:32-36, 1984
  • Chawla S.P., Benjamin R. S., Ewer M.S., Hortobagyi G. N., Legha S. S., Mackay B., Ali M. K., Carrasco C. H., Wallace S., Haynie III T. P., and Freireich E. J.: High cumulative dose Adriamycin beyond the conventional limits of 500 mg/m2 and reduction of cardiotoxicity by continuous infusion schedule.  (eds, Spitzy K. H. and Karrer K.), 13th International Congress of Chemotherapy, Vienna, Austria.  Verlag H. Egermann, 1983, pp. 546-550
  • Bhaduri S., Gupta R. C., Chawla S.P. and Mangalik A.: Chronic Granulocytic Leukemia: A Study of 177 cases. Indian J. of Cancer 16:1-7, 1979
  • Chawla S.P., Benjamin R. S., Legha S. S., Ewer M. S., Ali M. D., Mackay, B., Carrasco C. H., Hortobagyi G. N., Wallace S. Haynie III T. P., and Freireich E. J.: Role of cardiac biopsy and radionuclide scan in monitoring of adriamycin-induced cardiotoxicity.  (eds, Spitzy K. H. and Karrer K.), 13th International Congress of Chemotherapy, Vienna, Austria.  Verlag H. Egermann, 1983, pp. 490-492